Clinical trial
Use of Activated Recombinant FVII in Spinal Surgery
NCT00102037 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00102037 |
|---|---|
| Title | Use of Activated Recombinant FVII in Spinal Surgery |
| Official title | Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Spinal Fusion |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated) |
| Enrollment | 50 |
| Start date | Jul 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jan 20, 2005 |
| Last update posted | Jan 13, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: